Background: Bleeding is the leading cause of preventable death in trauma. Early identification of hemorrhage improves patient outcomes. Current triage tools for predicting hemorrhage rely on transfusion receipt as a surrogate outcome, indicating that blood was needed. This outcome does not account for misclassification of patients who receive prompt hemorrhage control procedure (HCP) without transfusion, patients who die before transfusion receipt, or those who receive unnecessary transfusion. Objective criteria that do not rely on transfusion receipt alone are needed to more accurately determine actionable hemorrhage and the appropriateness of transfusions in pediatric trauma patients.
Methods: We defined actionable hemorrhage within 6 hours of emergency department arrival as (1) actual or (2) estimated pretransfusion hemoglobin <8 g/dL, (3) performance of an HCP irrespective of transfusion receipt, or (4) death within 24 hours with an autopsy supporting bleeding as the cause of death. We applied this algorithm to 4,371 children (younger than 18 years) treated for blunt or penetrating injuries at three level 1 pediatric trauma centers between 2019 and 2021.
Results: A total of 4,201 children (96.1%) did not have actionable hemorrhage. One hundred sixty-four (3.8%) met the criteria for actionable hemorrhage, including 129 who were transfused within 6 hours. Transfusion receipt alone as an outcome missed 35 of 164 children (21.3%) with actionable hemorrhage: 19 who underwent an HCP and 16 with a hemoglobin level of <8 g/dL but not transfused within 6 hours. Thirty-eight of 167 children (22.8%) who received transfusion within 6 hours did not have actionable hemorrhage. Transfusion receipt as a test for actionable hemorrhage had a sensitivity of 78.7%, specificity of 99.1%, positive predictive value of 77.2%, negative predictive value of 99.2%, and Matthews correlation coefficient of 0.77.
Conclusion: Relying on transfusion receipt as a surrogate for actionable hemorrhage both underestimates and overestimates the actual need for intervention for hemorrhage. This study supports adjudicating actionable hemorrhage with a structured, criteria-based approach to more accurately ascertain this outcome.
Level Of Evidence: Diagnostic Test and Criteria; Level III.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/TA.0000000000004588 | DOI Listing |
Cureus
February 2025
Department of Breast Surgery, Osaka Rosai Hospital, Osaka, JPN.
and () mutation screening is recommended for patients with advanced breast cancer or early breast cancer suspected to have hereditary origins based on family history or tumor characteristics. Blood-based testing is the standard approach, but it is not feasible in patients who have undergone bone marrow transplantation due to the replacement of blood cells with donor-derived cells. We report a case of a patient who, following bone marrow transplantation, required an alternative to blood-based germline screening.
View Article and Find Full Text PDFExplor Target Antitumor Ther
February 2025
Department of Genetics, Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran 16635148, Iran.
Glioblastoma, an aggressive and lethal brain tumor, presents enormous clinical challenges, including molecular heterogeneity, high recurrence rates, resistance to conventional therapies, and limited therapeutic penetration across the blood-brain barrier. The glioblastoma microenvironment, characterized by a dynamic interplay of cellular and non-cellular components, is a key driver of tumor growth and therapeutic resistance. Neuroinflammatory cytokines, particularly interleukins and tumor necrosis factor-alpha, play pivotal roles in this microenvironment, contributing to tumor progression and immune evasion.
View Article and Find Full Text PDFCancer Med
March 2025
Huntsman Cancer Institute, Salt Lake City, Utah, USA.
Background: We investigated mental health diagnoses (MHDs) in mycosis fungoides (MF) patients compared to the general population, evaluated risk factors, and studied survival outcomes in a large population database.
Methods: MF patients from the Utah Cancer Registry diagnosed from 2001 to 2014 were matched with up to five general population individuals from the Utah Population Database. MHDs were retrospectively tracked in both populations (median follow-up = 6.
Cureus
February 2025
Institute for Human Movement and Medical Sciences, Niigata University of Health and Welfare, Niigata, JPN.
This report aimed to investigate the relationship between cerebral hemodynamics and orthostatic hypotension (OH) in a patient with acute exacerbation of chronic heart failure (HF) by measuring oxyhemoglobin (OHb) and regional cerebral oxygen saturation (rSO) using the wearable near-infrared spectroscopy (NIRS) device for risk management. A 61-year-old man was diagnosed with acute exacerbation of chronic HF. The patient was admitted to the hospital for the first time on day 0, and the first NIRS was performed on day 9.
View Article and Find Full Text PDFLancet Haematol
March 2025
Deptartment of Medicine 3, Haematology and Oncology, University Hospital Regensburg, Regensburg, Germany; Department for Epidemiology and Preventive Medicine, Division of Medical Sociology, University of Regensburg, Regensburg, Germany; Bavarian Cancer Research Center, Regensburg, Germany.
Graft-versus-host disease (GVHD) is a complication of hematopoietic cell transplantation (HCT) that has a low chance of complete remission and a substantial effect on morbidity and mortality. To better understand how to improve the field of GVHD research, management, and care, the cGVHD Eurograft Initiative organised a European community advisory board of patient advocates, with the assistance of the Lymphoma Coalition, to identify unmet needs. We present the results of this project in this Viewpoint, which identify unmet GVHD needs from the patient advocates' perspectives and provide five key actionable themes to improve GVHD management and care.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!